Design and Synthesis of Novel Cereblon Binders for Use in Targeted Protein Degradation
S Norris, X Ba, J Rhodes, D Huang… - Journal of Medicinal …, 2023 - ACS Publications
Modulating the chemical composition of cereblon (CRBN) binders is a critical step in the
optimization process of protein degraders that seek to hijack the function of this E3 ligase. Small …
optimization process of protein degraders that seek to hijack the function of this E3 ligase. Small …
[HTML][HTML] Oxamniquine derivatives overcome Praziquantel treatment limitations for Schistosomiasis
SN Alwan, AB Taylor, J Rhodes, M Tidwell… - PLoS …, 2023 - journals.plos.org
Human schistosomiasis is a neglected tropical disease caused by Schistosoma mansoni, S.
haematobium, and S. japonicum. Praziquantel (PZQ) is the method of choice for treatment. …
haematobium, and S. japonicum. Praziquantel (PZQ) is the method of choice for treatment. …
[HTML][HTML] Rational approach to drug discovery for human schistosomiasis
PT LoVerde, SN Alwan, AB Taylor, J Rhodes… - International Journal for …, 2021 - Elsevier
Human schistosomiasis is a debilitating, life-threatening disease affecting more than 229
million people in as many as 78 countries. There is only one drug of choice effective against all …
million people in as many as 78 countries. There is only one drug of choice effective against all …
Abstract 1022 Next-Generation Drugs for Schistosomiasis Therapy
S Alwan, T Alexander, J Rhodes, M Tidwell… - Journal of Biological …, 2024 - ASBMB
Human schistosomiasis, one of the most important neglected tropical diseases caused by
parasitic worms of the genus Schistosoma. It is accompanied by severe clinical symptoms as …
parasitic worms of the genus Schistosoma. It is accompanied by severe clinical symptoms as …
Development of Novel Broad-Range Antischistomal Agents by Structure-Based Design and Structure Activity Relationship Studies
J Rhodes - 2021 - search.proquest.com
Effecting more than 290 million people in over 78 countries and only one current treatment in
use, the parasitic disease human schistosomiasis is in danger of producing drug resistance …
use, the parasitic disease human schistosomiasis is in danger of producing drug resistance …
[PDF][PDF] Otilonium Bromide as an Antimicrobial: a Structure-Activity Relationship Study
J Rhodes, W Hua-Yu, A Cunningham, B Davies… - 2018 - rrpress.utsa.edu
The general structure of a quaternary ammonium compound (QAC) consist of a positively
charged quaternary amine and a lipophilic tail1 and pictured in figure 1 with a comparison to …
charged quaternary amine and a lipophilic tail1 and pictured in figure 1 with a comparison to …
Corrigendum to “Rational approach to drug discovery for human schistosomiasis”[Int. J. Parasitol. Drugs Drug Resist. 16 (2021) 140–147]
…, SN Alwan, AB Taylor, J Rhodes… - … : Drugs and Drug …, 2022 - ncbi.nlm.nih.gov
… Taylor, a Jayce Rhodes, c Frédéric D. Chevalier, d Timothy Jc Anderson, e and Stanton F.
McHardy c …
McHardy c …
The Development of Novel Therapeutics Against Schistosomiasis
…, RT Jr, CM Romero, AB Taylor, J Rhodes… - The FASEB …, 2020 - Wiley Online Library
Human schistosomiasis is a neglected tropical disease caused by parasitic worms. It affects
over 250 million people globally. Most human infections are caused by S. mansoni, S. …
over 250 million people globally. Most human infections are caused by S. mansoni, S. …
Structure-Based Drug Design and SAR Studies of Inhibitors Targeting Protein Kinase C Epsilon for Non-Opioid Pain Management
HC de Kraker - 2022 - search.proquest.com
The annual NIH report states that pain affects more Americans than diabetes, heart disease,
and cancer combined. Furthermore, chronic pain is the most common cause of long-term …
and cancer combined. Furthermore, chronic pain is the most common cause of long-term …
The Design, Synthesis, and Optimization of Di-Aryloxazole Inhibitors for the Treatment of Triple-Negative Breast Cancer
MG Glassman - 2021 - search.proquest.com
Triple-negative breast cancer (TNBC) accounts for 10-15% of all total breast cancer cases,
but has a much lower survival rate than its hormone-receptor counterparts. Currently, TNBC is …
but has a much lower survival rate than its hormone-receptor counterparts. Currently, TNBC is …